SUNPHARMA's weekly return of 0.49% was modest, accompanied by a relatively high volatility of 17.34%. Compared to its peers, SUNPHARMA underperformed DRREDDY and DIVISLAB, but outperformed HINDUNILVR. The stock's Sharpe Ratio of 0.12 indicates a relatively low risk-adjusted return, and its Max Drawdown of -1.26% suggests a moderate level of risk. Overall, SUNPHARMA's weekly performance was lackluster, with room for improvement.

[Volatility: 17.34%]